1. Scrip
  2. >>Business
  3. >>Deals

Roche Partnering Casts Wide Net To Expand Company’s Neuroscience Pipeline

 
• By Mandy Jackson

Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.

Zioncheck_Tom_1200.jpg
Roche Partnering's Tom Zioncheck leads neuroscience deal-making • Source: Roche

Tom Zioncheck, head of neuroscience, ophthalmology and rare diseases partnering for Roche and Genentech Inc., told Scrip that 2019 was a “remarkable” year for the company’s pharma partnering group, because the team negotiated 80 significant transactions. That number includes several deals in neuroscience – a therapeutic area where the Swiss big pharma hopes to create a presence similar to its dominant position in oncology.

Zioncheck noted in an interview during the recent J.P. Morgan Healthcare Conference in San Francisco that Roche is building on the success it has seen in neuroscience with the instant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

More from Business

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.